Alnylam Pharma (ALNY) Tops Q1 EPS by 98c; reiterates guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $312.78 +3.68%
Revenue Growth %: +70.6%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
PKE, LNN, More
Revenue Growth %: +70.6%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
PKE, LNN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.16), $0.98 better than the analyst estimate of ($1.14). Revenue for the quarter came in at $494.33 million versus the consensus estimate of $428.05 million.
GUIDANCE:
Alnylam Pharma sees FY2024 revenue of $1.4-1.5 billion, versus the consensus of $1.853 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $470 at H.C. Wainwright
- Six Flags names Mark Pauls as chief operating officer
- Lindsay (LNN) Tops Q3 EPS by 18c, Misses on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
